Dosimetry and first human experience with <sup>89</sup>Zr-panitumumab.

Dosimetry and first human experience with ⁸⁹Zr-panitumumab.

Lindenberg, Liza; Adler, Stephen; Turkbey, Ismail B; Mertan, Francesca; Ton, Anita; Do, Khanh; Kummar, Shivaani; Gonzalez, Esther Mena; Bhattacharyya, Sibaprasad; Jacobs, Paula M; Choyke, Peter.

Afiliação

Lindenberg L; Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of HealthBethesda, MD, USA.
Adler S; Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer ResearchFrederick, Maryland 21702, USA.
Turkbey IB; Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of HealthBethesda, MD, USA.
Mertan F; Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of HealthBethesda, MD, USA.
Ton A; Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer ResearchFrederick, Maryland 21702, USA.
Do K; Dana-Farber Cancer InstituteBoston, MA, USA.
Kummar S; Stanford University School of MedicinePalo Alto, CA, USA.
Gonzalez EM; Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of HealthBethesda, MD, USA.
Bhattacharyya S; Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug AdministrationSilver Spring, MD, USA.
Jacobs PM; Cancer Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of HealthBethesda, MD, USA.
Choyke P; Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of HealthBethesda, MD, USA.